Plus Therapeutics, Inc. financial data

Symbol
PSTV on Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
Location
4200 Marathon Blvd., Suite 200, Austin, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
CYTORI THERAPEUTICS, INC. (to 8/2/2019), MACROPORE INC (to 7/5/2005)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 55.3 % -56.6%
Debt-to-equity -285 % -178%
Return On Equity 271 %
Return On Assets -146 % -61.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.9M shares +30.4%
Common Stock, Shares, Outstanding 5.9M shares +30.4%
Entity Public Float 5.8M USD -52.1%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 7.86M shares +144%
Weighted Average Number of Shares Outstanding, Diluted 7.86M shares +144%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.2M USD +23.9%
General and Administrative Expense 9.19M USD -5.77%
Operating Income (Loss) -14.7M USD +2.54%
Nonoperating Income (Expense) 1.77M USD +2791%
Net Income (Loss) Attributable to Parent -12.9M USD +15%
Earnings Per Share, Basic -2.15 USD/shares +75.1%
Earnings Per Share, Diluted -2.41 USD/shares +72.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.22M USD -88.9%
Other Assets, Current 576K USD +18.3%
Assets, Current 5.36M USD -53.7%
Property, Plant and Equipment, Net 591K USD -41.4%
Operating Lease, Right-of-Use Asset 106K USD -54.3%
Goodwill 372K USD 0%
Other Assets, Noncurrent 32K USD 0%
Assets 6.98M USD -47.4%
Accounts Payable, Current 4.76M USD -43.1%
Liabilities, Current 12.1M USD +14.9%
Operating Lease, Liability, Noncurrent 40K USD -66.1%
Liabilities 12.2M USD +14%
Retained Earnings (Accumulated Deficit) -490M USD -2.7%
Stockholders' Equity Attributable to Parent -5.17M USD -297%
Liabilities and Equity 6.98M USD -47.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.51M USD +22.1%
Net Cash Provided by (Used in) Financing Activities -776K USD -257%
Net Cash Provided by (Used in) Investing Activities -364K USD -275%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 6.15M shares +36.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.65M USD -4.74%
Interest Paid, Excluding Capitalized Interest, Operating Activities 23K USD -68.5%
Deferred Tax Assets, Valuation Allowance 19.5M USD +21.1%
Deferred Tax Assets, Gross 19.5M USD +21%
Operating Lease, Liability 205K USD -18.3%
Payments to Acquire Property, Plant, and Equipment 40K USD -58.8%
Lessee, Operating Lease, Liability, to be Paid 217K USD -19%
Property, Plant and Equipment, Gross 3.44M USD +4.81%
Operating Lease, Liability, Current 68K USD -41.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 60K USD -46.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 146K USD +6.57%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +22.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12K USD -29.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11K USD -38.9%
Deferred Tax Assets, Operating Loss Carryforwards 13.4M USD +6.28%
Preferred Stock, Shares Issued 1.95K shares 0%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 408K USD +95.2%
Operating Lease, Payments 148K USD -26.7%
Additional Paid in Capital 485M USD +1.17%
Preferred Stock, Shares Outstanding 1.95K shares 0%
Depreciation, Depletion and Amortization 155K USD -1.9%
Deferred Tax Assets, Net of Valuation Allowance 43K USD -18.9%
Interest Expense 210K USD -63.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%